| Literature DB >> 27449326 |
Hyung Sook Kim1, Ki Hwan Park1, Hong Kyung Lee1, Ji Sung Kim1, Yong Guk Kim1, Jae Hee Lee1, Ki Hun Kim1, Jieun Yun2, Bang Yeon Hwang1, Jin Tae Hong1, Youngsoo Kim1, Sang-Bae Han3.
Abstract
Curdlan, a β-1,3-glucan isolated from Alcaligenes faecalis, is an agonist of dectin-1 in various immune cells, including dendritic cells (DCs). However, whether curdlan also activates DCs through other receptors remains unknown. In this study, we found that curdlan activates DCs through dectin-1 and toll-like receptor 4 (TLR4). Curdlan increased the expression levels of surface molecules (CD40, CD80, CD86, and MHC-I/II), the production of cytokines (IL-12, IL-1β, TNF-α, and IFN-β), migration toward MIP-3β, and allogeneic T cell stimulation activity of DCs. Curdlan increased the phosphorylation of Syk, Raf-1, Akt, MAPKs, IKK, and NF-κB p65 in DCs. However, curdlan only slightly activated DCs transfected with small interfering RNAs against dectin-1 or TLR4 and C3H/HeJ DCs, which have non-functional TLR4, in comparison with control DCs. Curdlan increased antitumor activity of DCs in a syngeneic tumor model. In summary, our data show that curdlan activates DCs through dectin-1 and TLR4 signaling and the combination of curdlan and DCs efficiently inhibit tumor growth in mice.Entities:
Keywords: Adjuvant; C3H/HeJ; Cancer immunotherapy; siRNA
Mesh:
Substances:
Year: 2016 PMID: 27449326 DOI: 10.1016/j.intimp.2016.07.013
Source DB: PubMed Journal: Int Immunopharmacol ISSN: 1567-5769 Impact factor: 4.932